European CHMP clarifies Pfizer/BioNTech COVID-19 vaccine (Comirnaty) dosage interval

The EU product information for Comirnaty has been updated to clarify the European CHMP’s position on the interval between doses. It now recommends the second dose be administered 3 weeks after the first dose (previously stated the interval should be “at least 21 days”).

SPS commentary:

The product information already states that the participants whose data was used to calculate efficacy received their second dose within 19 to 42 days after their first dose. A sentence has been added to note that 93.1% of these participants received the second dose 19 to 23 days after the first dose.


European Medicines Agency